QUIGLEY (NASDAQ:QGLY)
2.29
+0.14 (6.51%)
| QUIGLEY (NASDAQ:QGLY) Delayed : |
| Previous Close |
$2.15 |
|
52 Week High |
$6.70 |
|
| Open |
$2.15 |
|
52 Week Low |
$1.58 |
| Day High |
$2.30 |
|
P/E |
N/A |
| Day Low |
$2.15 |
|
EPS |
$-0.59 |
| Volume |
1,615 |
|
|
|
| More QGLY Info:
Chart
SEC Filings
Profile
Historical
Options
|
View All ReportsStreetInsider.com Reports on QGLY
-
Nov 12, 2009 08:37 AM
Quigley (QGLY) Posts Q3 Loss of 9c, Down Y/Y; Revs Lower
-
Nov 11, 2009 03:05 PM
Trading Radar for 11/12: Wal-Mart (WMT), Blockbuster (BBI), Nordstrom (JWN), Walt Disney (DIS), Kohl's (KSS) Report
-
Aug 18, 2009 09:26 AM
Morning Movers 8/18: ISR, HURN, POR, QGLY, TSEM, NVAX, CHINA Higher; RPRX, GERN, DFG Lower
-
Jul 22, 2009 08:25 AM
Quigley Corporation (QGLY) Announces Final Results of Quigley Pharma's Phase IIb Study
-
Jul 17, 2009 08:42 AM
Quigley Corporation (QGLY) Names Ted Karkus as CEO
View All Reports
StreetInsider Reports on QGLY by Category
Comments on recent QGLY articles
Comments on QGLY
No comments are currently available.
on Aug 18, 2009
at 11:42 PM Quigley's new board They ruined a small town "family" business in this proxy battle an don't let this guy Karkus snow the public. For all his complaining about executive compensation, he's taking $750,000 a year and being a new yorker probably isn't there every day. What a sham!
Article: Quigley Corporation (QGLY) Names Ted Karkus as CEO
on Apr 28, 2009
at 09:13 AM money makers that will save- prolong life provectus pharma pvct another cancer cure +++ dandrion DNDN jump on board
Article: U.S. Issues Public Health Emergency About Swine Flu
on Apr 27, 2009
at 10:40 PM i see what you mean that stock finished up over 18% for the day on big volume. that's a much bigger gain than most of those stocks mentioned by hot list - and it was much higher earlier in the day. http://cxa.marketwatch.com/tsx/en/market/quote.aspx?symbol=rbm
Article: U.S. Issues Public Health Emergency About Swine Flu
on Apr 27, 2009
at 10:16 PM 3M Rapid Detection Flu A+B Test I am surprised that this article didn't mention Response Biomedical (TSX: RBM), which makes the rapid flu test marketed by 3M as the 3M Rapid Detection Flu A + B Test. It was just launched in the fall and is a more accurate and sophisticated test than the other point of care tests on the market, like Quidel. By the way, RBM is also partnered with Roche (maker of Tamiflu) in an agreement to supply all of Roche's point of care cardiology tests and Cardiac Readers, which just launched in March of April.
Article: U.S. Issues Public Health Emergency About Swine Flu